Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Toxicity of Inhaled Ciclesonide in Preterm Infants at Risk for BPD
NCT06589245Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ciclesonide in bronchopulmonary dysplasia (BPD) (2 arms). Primary endpoints: Number of hyperglycemia events at 4 months, Average change in z-scores for weight, length, and head circumference at 4 months and 6 more. Started Sep 2025; status: recruiting.
02
Drugs
ciclesonide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT06589245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589245.